MA54229A - Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp - Google Patents
Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrpInfo
- Publication number
- MA54229A MA54229A MA054229A MA54229A MA54229A MA 54229 A MA54229 A MA 54229A MA 054229 A MA054229 A MA 054229A MA 54229 A MA54229 A MA 54229A MA 54229 A MA54229 A MA 54229A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- compounds
- treatment
- diseases associated
- nlrp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760209P | 2018-11-13 | 2018-11-13 | |
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US201862768811P | 2018-11-16 | 2018-11-16 | |
| US201862769151P | 2018-11-19 | 2018-11-19 | |
| US201862769165P | 2018-11-19 | 2018-11-19 | |
| US201962795919P | 2019-01-23 | 2019-01-23 | |
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US201962836575P | 2019-04-19 | 2019-04-19 | |
| US201962836577P | 2019-04-19 | 2019-04-19 | |
| US201962836585P | 2019-04-19 | 2019-04-19 | |
| US201962895595P | 2019-09-04 | 2019-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54229A true MA54229A (fr) | 2022-02-16 |
Family
ID=68841175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054229A MA54229A (fr) | 2018-11-13 | 2019-11-11 | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20230031406A1 (fr) |
| EP (1) | EP3880660A1 (fr) |
| JP (2) | JP2022507065A (fr) |
| KR (1) | KR20210096123A (fr) |
| CN (1) | CN113166065A (fr) |
| AU (1) | AU2019379109B2 (fr) |
| BR (1) | BR112021008969A2 (fr) |
| CA (1) | CA3114918A1 (fr) |
| CL (1) | CL2021001228A1 (fr) |
| CO (1) | CO2021006075A2 (fr) |
| CR (1) | CR20210235A (fr) |
| EC (2) | ECSP21033236A (fr) |
| IL (1) | IL283042B1 (fr) |
| JO (1) | JOP20210105A1 (fr) |
| MA (1) | MA54229A (fr) |
| MX (1) | MX2021005529A (fr) |
| PE (1) | PE20211698A1 (fr) |
| SG (1) | SG11202103405TA (fr) |
| TW (1) | TW202031647A (fr) |
| WO (1) | WO2020102096A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008029A1 (fr) * | 2017-07-07 | 2019-01-10 | Inflazome Limited | Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3 |
| WO2019034693A1 (fr) | 2017-08-15 | 2019-02-21 | Inflazome Limited | Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3 |
| US11613542B2 (en) | 2017-08-15 | 2023-03-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| EP3668842A1 (fr) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3 |
| CA3078195A1 (fr) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Nouveaux composes de sulfonamide carboxamide |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| CN117105890A (zh) | 2019-11-12 | 2023-11-24 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN115461120A (zh) * | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 |
| WO2022023907A1 (fr) | 2020-07-31 | 2022-02-03 | Novartis Ag | Méthodes de sélection et de traitement de patients présentant un risque élevé d'événements cardiaques indésirables majeurs |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| WO2022237782A1 (fr) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | Dérivé d'amide et son application |
| TWI815439B (zh) * | 2021-05-10 | 2023-09-11 | 大陸商成都百裕製藥股份有限公司 | 醯胺衍生物及其應用 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41553B1 (fr) * | 2015-02-16 | 2020-04-30 | The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv | Sulfonylurées, composés apparentés, et leur utilisation |
| JP2019518071A (ja) * | 2016-04-18 | 2019-06-27 | アイエフエム トレ インコーポレイテッド | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| BR112020001476A2 (pt) * | 2017-07-24 | 2020-09-15 | Novartis Inflammasome Research, Inc. | compostos e composições para tratar condições associadas à atividade nlrp |
-
2019
- 2019-11-11 KR KR1020217017180A patent/KR20210096123A/ko unknown
- 2019-11-11 BR BR112021008969-1A patent/BR112021008969A2/pt unknown
- 2019-11-11 CA CA3114918A patent/CA3114918A1/fr active Pending
- 2019-11-11 AU AU2019379109A patent/AU2019379109B2/en active Active
- 2019-11-11 CN CN201980074397.XA patent/CN113166065A/zh active Pending
- 2019-11-11 MA MA054229A patent/MA54229A/fr unknown
- 2019-11-11 WO PCT/US2019/060770 patent/WO2020102096A1/fr active Application Filing
- 2019-11-11 IL IL283042A patent/IL283042B1/en unknown
- 2019-11-11 SG SG11202103405TA patent/SG11202103405TA/en unknown
- 2019-11-11 MX MX2021005529A patent/MX2021005529A/es unknown
- 2019-11-11 JO JOP/2021/0105A patent/JOP20210105A1/ar unknown
- 2019-11-11 PE PE2021000700A patent/PE20211698A1/es unknown
- 2019-11-11 JP JP2021525223A patent/JP2022507065A/ja active Pending
- 2019-11-11 EP EP19817831.1A patent/EP3880660A1/fr active Pending
- 2019-11-11 CR CR20210235A patent/CR20210235A/es unknown
- 2019-11-11 US US17/292,881 patent/US20230031406A1/en active Pending
- 2019-11-13 TW TW108141175A patent/TW202031647A/zh unknown
-
2021
- 2021-05-10 CO CONC2021/0006075A patent/CO2021006075A2/es unknown
- 2021-05-11 CL CL2021001228A patent/CL2021001228A1/es unknown
- 2021-05-11 EC ECSENADI202133236A patent/ECSP21033236A/es unknown
-
2024
- 2024-06-05 JP JP2024091521A patent/JP2024113083A/ja active Pending
- 2024-06-07 EC ECSENADI202444340A patent/ECSP24044340A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022507065A (ja) | 2022-01-18 |
| CL2021001228A1 (es) | 2021-12-31 |
| ECSP24044340A (es) | 2024-07-31 |
| CA3114918A1 (fr) | 2020-05-22 |
| US20230031406A1 (en) | 2023-02-02 |
| JP2024113083A (ja) | 2024-08-21 |
| IL283042A (en) | 2021-06-30 |
| BR112021008969A2 (pt) | 2021-08-03 |
| WO2020102096A1 (fr) | 2020-05-22 |
| AU2019379109A1 (en) | 2021-05-06 |
| TW202031647A (zh) | 2020-09-01 |
| ECSP21033236A (es) | 2021-06-30 |
| IL283042B1 (en) | 2024-08-01 |
| CO2021006075A2 (es) | 2021-05-31 |
| AU2019379109B2 (en) | 2022-07-07 |
| JOP20210105A1 (ar) | 2023-01-30 |
| EP3880660A1 (fr) | 2021-09-22 |
| PE20211698A1 (es) | 2021-09-01 |
| CR20210235A (es) | 2021-06-30 |
| MX2021005529A (es) | 2021-06-18 |
| SG11202103405TA (en) | 2021-05-28 |
| CN113166065A (zh) | 2021-07-23 |
| KR20210096123A (ko) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| MA53096A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
| MA56047A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting | |
| MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
| MA53095A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
| MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| MA56193A (fr) | Composés et compositions pour traiter des états associés à une activité de sting | |
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| DK3906066T5 (da) | Geneterapikonstruktioner til behandling af wilsons sygdom | |
| ECSP21093541A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| MA55974A (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| MA55138A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| BR112018011308A2 (pt) | anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| MA53170A (fr) | Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| MA54753A (fr) | Composés et compositions pour traiter des états pathologiques associés à une activité de sting | |
| MA50905A (fr) | Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques | |
| MA54515A (fr) | Dérivés de quinoléine destinés à être utilisés dans le traitement de maladies inflammatoires | |
| MA52873A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
| SG11202011018PA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
| SG11202011010YA (en) | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization | |
| MA53875A (fr) | Traitement avec des compositions d'igg hautement sialylées |